SYK and breast cancer: Notably, fostamatinib, a spleen tyrosine kinase inhibitor used for chronic immune thrombocytopenia after other treatments, targets ULK3 (Supplementary Table S5), which shows promise as a new therapeutic target for breast cancer treatment and as a prognostic biomarker.